Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT1 | P35610 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1803256 | 1.00 | SOAT1 (0.50) | SOAT1MEN1POLBKMT2AATM | |
| SCHEMBL12244568 | 0.96 | SOAT1 (0.48) | SOAT1MEN1POLBKMT2AATM | |
| SCHEMBL12654166 | 0.81 | SOAT1 (0.53) | SOAT1 | |
| SCHEMBL1801445 | 0.81 | SOAT1 (0.38) | SOAT1 | |
| SCHEMBL12620845 | 0.81 | SOAT1 (0.38) | SOAT1 | |
| SCHEMBL12620847 | 0.80 | SOAT1 (0.43) | SOAT1 | |
| SCHEMBL1808525 | 0.80 | SOAT1 (0.43) | SOAT1 | |
| SCHEMBL12620818 | 0.80 | SOAT1 (0.41) | SOAT1 | |
| SCHEMBL8619226 | 0.77 | SOAT1 (0.41) | SOAT1 | |
| SCHEMBL12620807 | 0.77 | SOAT1 (0.38) | SOAT1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144870-A1 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-12636318-B2 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-12622930-B2 | Pharmaceutical composition for preventing or treating brain disease, comprising stem cell-derived exosome surface-modified with compound capable of binding to dopamine receptors or L-amino acid transporters | Research & Business Foundation Sungkyunkwan University (KR) | 2026-05-12 | — | — | US | disclosed |
| US-12622927-B2 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-12611428-B2 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-12611429-B2 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-12570959-B2 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12558375-B2 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-12485145-B2 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250361572-A1 | MULTIPLEXED PATHOGEN DETECTION USING NANOPLASMONIC SENSOR FOR HUMAN PAPILLOMAVIRUS | NANOPATH INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20220204932-A1 | PROCESSES FOR GENERATING TIL PRODUCTS ENRICHED FOR TUMOR ANTIGEN-SPECIFIC T-CELLS | IOVANCE BIOTHERAPEUTICS, INC. | 2022-06-30 | — | — | US | disclosed |
| US-11344579-B2 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-11337998-B2 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20220118011-A1 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | IOVANCE BIOTHERAPEUTICS, INC. | 2022-04-21 | — | — | US | disclosed |
| US-11304979-B2 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2022-04-19 | — | — | US | disclosed |
| US-11291687-B2 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2022-04-05 | — | — | US | disclosed |
| US-11273180-B2 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-11273181-B2 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-11254913-B1 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-11241456-B2 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2022-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12558375-B2 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | IL2, PBK, TAP2 | SOAT1 628/4885MEN1 4885/4885POLB 783/4885 |
| US-12636318-B2 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | IL2, PBK, ICOS | SOAT1 774/4885MEN1 4863/4885POLB 893/4885 |
| US-20260144870-A1 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | PBK, ITK, IL2 | SOAT1 548/4885MEN1 4643/4885POLB 1172/4885 |
| US-12611429-B2 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | IL2, PBK, ICOS | SOAT1 549/4885MEN1 4841/4885POLB 1626/4885 |
| US-12611428-B2 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | IL2, ICOS, CD274 | SOAT1 359/4885MEN1 4715/4885POLB 454/4885 |
| US-12622930-B2 | Pharmaceutical composition for preventing or treating brain disease, comprising stem cell-derived exosome surface-modified with compound capable of binding to dopamine receptors or L-amino acid transporters | SLC18A2, SLC6A3, SLC18A3 | SOAT1 3994/4885MEN1 4520/4885POLB 2635/4885 |
| US-12570959-B2 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | IL2, PBK, ICOS | SOAT1 785/4885MEN1 4862/4885POLB 1362/4885 |
| US-12622927-B2 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | IL2, PBK, ICOS | SOAT1 771/4885MEN1 4723/4885POLB 930/4885 |
| US-20220118011-A1 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | ICOS, PBK, IL2 | SOAT1 1654/4885MEN1 4264/4885POLB 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.